GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Cyclically Adjusted Revenue per Share

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Cyclically Adjusted Revenue per Share : $4.04 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Santen Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2024 was $1.449. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $4.04 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Santen Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 10.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Santen Pharmaceutical Co was 10.50% per year. The lowest was 8.40% per year. And the median was 9.15% per year.

As of today (2024-05-14), Santen Pharmaceutical Co's current stock price is $10.245. Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $4.04. Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 2.54.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Santen Pharmaceutical Co was 5.62. The lowest was 1.77. And the median was 3.67.


Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Santen Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.97 4.26 4.16 4.27 4.04

Santen Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.27 4.03 3.99 4.32 4.04

Competitive Comparison of Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.



Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Santen Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.449/107.2000*107.2000
=1.449

Current CPI (Mar. 2024) = 107.2000.

Santen Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.797 98.000 0.872
201409 0.858 98.500 0.934
201412 0.906 97.900 0.992
201503 0.901 97.900 0.987
201506 0.933 98.400 1.016
201509 0.999 98.500 1.087
201512 1.015 98.100 1.109
201603 0.981 97.900 1.074
201606 1.142 98.100 1.248
201609 1.131 98.000 1.237
201612 1.114 98.400 1.214
201703 1.052 98.100 1.150
201706 1.237 98.500 1.346
201709 1.214 98.800 1.317
201712 1.255 99.400 1.353
201803 1.302 99.200 1.407
201806 1.257 99.200 1.358
201809 1.264 99.900 1.356
201812 1.285 99.700 1.382
201903 1.351 99.700 1.453
201906 1.367 99.800 1.468
201909 1.385 100.100 1.483
201912 1.455 100.500 1.552
202003 1.375 100.300 1.470
202006 1.337 99.900 1.435
202009 1.451 99.900 1.557
202012 1.513 99.300 1.633
202103 1.558 99.900 1.672
202106 1.474 99.500 1.588
202109 1.446 100.100 1.549
202112 1.470 100.100 1.574
202203 1.484 101.100 1.574
202206 1.231 101.800 1.296
202209 1.164 103.100 1.210
202212 1.359 104.100 1.399
202303 1.570 104.400 1.612
202306 1.369 105.200 1.395
202309 1.373 106.200 1.386
202312 1.507 106.800 1.513
202403 1.449 107.200 1.449

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Santen Pharmaceutical Co  (OTCPK:SNPHY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=10.245/4.04
=2.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Santen Pharmaceutical Co was 5.62. The lowest was 1.77. And the median was 3.67.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood 04-23-2020

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood 04-23-2020